


1-13896



02027783

P.E 4.22.02

REC'D S.E.C.
APR 24 2002
080

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the period ended April 22, 2002

PROCESSED
MAY 08 2002

Elan Corporation, plc
(Translation of registrant's name into English)

THOMSON
FINANCIAL

Lincoln House, Lincoln Place, Dublin 2, Ireland
(Address of principal executive offices)

Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by fur-
nishing the information contained in this Form is also thereby
furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

FOR IMMEDIATE RELEASE

Contacts:

Investors: (U.S.)

Jack Howarth

Ph: 212-407-5740

800-252-3526

Investors: (Europe)

Emer Reynolds

Ph: 353-1-709-4000

00800 28352600

**ELAN ANNOUNCES WEBCAST OF FIRST QUARTER 2002
FINANCIAL RESULTS**

DUBLIN, IRELAND, April 22, 2002 -- Elan Corporation, plc (NYSE: ELN) ("Elan") announced today that it will report first quarter 2002 financial results on May 2, 2002, before the financial markets open. The announcement will be followed by a conference call at 8:30 a.m. Eastern Time with the investment community, and feature members of Elan's Senior Management Team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call is expected to last approximately one hour.

This event can be accessed by to Elan's website, www.elan.com, and clicking on the Investor Relations section, then on the event icon. The event will be archived and available for replay for 48 hours after the event.

Elan Corporation, plc. is a leading worldwide, fully integrated biopharmaceutical company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland and the United States. Elan is focused on the marketing of therapeutic products and services in neurology, pain management, oncology, infectious disease and dermatology and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies. Elan shares trade on the New York, London and Dublin Stock Exchanges.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELAN CORPORATION, plc

By: _____

William F. Daniel
Company Secretary

Date: April 24, 2002